Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by barcodewhizon Jan 07, 2005 12:45pm
198 Views
Post# 8401207

RE: nice start eom

RE: nice start eom Good post Stoocks... I agree with you for the most part but not entirely. The fact is the company has done a really good job of developing the multiple business platforms that now exist. These platforms give the company necessary diversity. Diversity that is RARE in a company of this size and maturity. There's no argument whatsoever that these things have taken longer than anticipated and have costed more than expected but I think its fair to argue that virtually every platform has developed BETTER than we thought they would 3 years ago... MacoPharma / PRDT alliance ; Proprietary.. novel... well positioned Plasma Fractionation program... proprietary... solid contract future PBI-1402: outstanding preliminary results.. great JV prospects Enabling business: solid contracts with fortune 500 co's and expanding Its not terribly difficult to create a cash flow positive company for that sake of a cash flow positive company, you either just cut your R&D or you sell the future. We all have to recognize that its very difficult to fundamentally change the markets adoption pace of new and proprietary technologies. I would much rather be cash flow neutral to negative for another year if you are doubling or tripling the 2-3 or 4 year income streams via solid contracts. The key is they are SOLID contracts with REAL revenue and royalties... as evidenced by the recent ramp in recurring revenue. Far too often the market pressures companies into a short term focus. I applaud Prometic for not bowing to that pressure despite unforseen delays. The fact is, we simply havent been able to have it both ways. ie: cash flow positive now and big downstream value. There's no question that management has been overoptimistic in terms of TIMING, but the degree of the opportunity has been well measured. Ironically, as Ruttan pointed out... this argument may well be moot very shortly because it looks like everything is coming to fruition. The difference here is, because of managements poor communications and expectation settings, we are not getting anywhere near the value recognition NOW in the market. You are right in that they simply wont be able to argue with cash
Bullboard Posts